Cyril Amarchand Mangaldas advised Enzene Biosciences Limited (Enzene Biosciences) on acquisition of 8% minority stake in Enzene Biosciences (a subsidiary of Alkem Laboratories Limited) by Eight Roads Ventures and F-Prime Capital, for a total consideration of INR 161 crores (approx.)
The General Corporate Law Practices of Cyril Amarchand Mangaldas acted as the legal counsel for Enzene Biosciences on the transaction. The transaction team was led by Nagavalli G, Partner; with support from Ayushi Mishra, Senior Associate.
As a part of the Transaction, Eight Roads Ventures and F-Prime Capital acquired a minority stake in Enzene Biosciences through two separate non- resident funds, by subscribing to equity and preference shares of Enzene Biosciences.
The Transaction was signed on 23rd December 2022.
About Cyril Amarchand Mangaldas
Cyril Amarchand Mangaldas (cam) is India’s leading law firm with a global reputation of being trusted advisers to its clients. The Firm advises a large and diverse set of clients, including domestic and foreign commercial enterprises, financial institutions, private equity and venture capital funds, start-ups, government and regulatory bodies. The Firm generalists, specialists and senior ex-regulators expertly guide clients across a spectrum of transactions, sectors and regulations. With 1000 lawyers and 160 Partners, the Firm is the largest full-service law firm in India and offices in key business centres at Mumbai, Delhi-NCR, Bengaluru, Ahmedabad, Hyderabad, Chennai, GIFT City and also in Singapore.
The Firm recently received “Innovation in Advancing Markets” award at the FT Innovative Lawyers Asia Pacific 2022 Awards and the “National Law Firm of the Year: India” award at the IFLR Asia Pacific 2022 awards ceremony. The Firm had won “India Deal Firm of the Year” at the ALB India Awards and “Firm of the Year” at the IFLR1000 India Awards in 2021.
